{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:42:35Z","timestamp":1792590155705,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.eclinm.2019.100254","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T05:18:28Z","timestamp":1580102308000},"page":"100254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study"],"prefix":"10.1016","volume":"19","author":[{"given":"Raul","family":"Juntas-Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pageot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkarim","family":"Bendarraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Alphand\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Seigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Camu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eclinm.2019.100254_bib0001","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrneurol.2011.153","article-title":"Clinical diagnosis and management of amyotrophic lateral sclerosis","volume":"7","author":"Hardiman","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"10.1016\/j.eclinm.2019.100254_bib0002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole study group","volume":"330","author":"Bensimon","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eclinm.2019.100254_bib0003","first-page":"51","article-title":"Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase","volume":"44","author":"Gurney","year":"1996","journal-title":"Pathol Biol"},{"issue":"20","key":"10.1016\/j.eclinm.2019.100254_bib0004","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0b013e3181c1df48","article-title":"Smoking may be considered an established risk factor for sporadic ALS","volume":"73","author":"Armon","year":"2009","journal-title":"Neurology"},{"issue":"Pt 3","key":"10.1016\/j.eclinm.2019.100254_bib0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/brain\/awh373","article-title":"Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players","volume":"128","author":"Chio","year":"2005","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.eclinm.2019.100254_bib0006","first-page":"181","article-title":"Risk factors for amyotrophic lateral sclerosis","volume":"7","author":"Ingre","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.eclinm.2019.100254_bib0007","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.neurobiolaging.2013.11.005","article-title":"Vitamin d confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis","volume":"35","author":"Camu","year":"2014","journal-title":"Neurobiol Aging"},{"issue":"5-6","key":"10.1016\/j.eclinm.2019.100254_bib0008","first-page":"310","article-title":"Prognostic factors in ALS: a critical review","volume":"10","author":"Chio","year":"2009","journal-title":"Amyotroph Lateral Scler Off Publ World Fed Neurol Res Group Motor Neuron Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2019.100254_bib0009","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00415-010-5805-z","article-title":"Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis","volume":"258","author":"Dorst","year":"2011","journal-title":"J Neurol"},{"issue":"13","key":"10.1016\/j.eclinm.2019.100254_bib0010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","article-title":"Dyslipidemia is a protective factor in amyotrophic lateral sclerosis","volume":"70","author":"Dupuis","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.eclinm.2019.100254_bib0011","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/ene.12754","article-title":"Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis","volume":"22","author":"Patin","year":"2015","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.eclinm.2019.100254_bib0012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clnu.2011.06.004","article-title":"Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients","volume":"30","author":"Genton","year":"2011","journal-title":"Clin Nutr (Edinburgh, Scotland)."},{"key":"10.1016\/j.eclinm.2019.100254_bib0013","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.neuroscience.2010.10.040","article-title":"Deregulation of the hypoxia inducible factor-1alpha pathway in monocytes from sporadic amyotrophic lateral sclerosis patients","volume":"172","author":"Moreau","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.eclinm.2019.100254_bib0014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fncel.2015.00341","article-title":"Ultrastructural studies of ALS mitochondria connect altered function and permeability with defects of mitophagy and mitochondriogenesis","volume":"9","author":"Ruffoli","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"10.1016\/j.eclinm.2019.100254_bib0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nn.3357","article-title":"Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis","volume":"16","author":"Kang","year":"2013","journal-title":"Nat Neurosci"},{"issue":"Pt 2","key":"10.1016\/j.eclinm.2019.100254_bib0016","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/brain\/aws339","article-title":"Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis","volume":"136","author":"Philips","year":"2013","journal-title":"Brain J Neurol"},{"issue":"5","key":"10.1016\/j.eclinm.2019.100254_bib0017","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00018-012-1096-0","article-title":"Structure and function of biotin-dependent carboxylases","volume":"70","author":"Tong","year":"2013","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"3","key":"10.1016\/j.eclinm.2019.100254_bib0018","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nbd.2012.04.016","article-title":"Neurological deficits in mice with profound biotinidase deficiency are associated with demylination and axonal degeneration","volume":"47","author":"Pindolia","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.eclinm.2019.100254_bib0019","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.msard.2015.01.005","article-title":"High doses of biotin in chronic progressive multiple sclerosis: a pilot study","volume":"4","author":"Sedel","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"13","key":"10.1016\/j.eclinm.2019.100254_bib0020","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1177\/1352458516667568","article-title":"MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study","volume":"22","author":"Tourbah","year":"2016","journal-title":"Mult Scler"},{"issue":"Pt B","key":"10.1016\/j.eclinm.2019.100254_bib0021","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.neuropharm.2015.08.028","article-title":"Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis","volume":"110","author":"Sedel","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eclinm.2019.100254_bib0022","unstructured":"World Medical Association. Declaration of helsinki: Ethical principles for medical research involving human subjects Available from: https:\/\/www.wma.net\/what-we-do\/medical-ethics\/declaration-of-helsinki\/."},{"issue":"3","key":"10.1016\/j.eclinm.2019.100254_bib0023","first-page":"135","article-title":"Are the el escorial and revised el escorial criteria for ALS reproducible? A study of inter-observer agreement. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the world federation of neurology","volume":"2","author":"Forbes","year":"2001","journal-title":"Res Group Motor Neuron Dis"},{"issue":"1-2","key":"10.1016\/j.eclinm.2019.100254_bib0024","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2008.07.016","article-title":"ALSFRS-R score and its ratio: a useful predictor for ALS-progression","volume":"275","author":"Kollewe","year":"2008","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.eclinm.2019.100254_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000194316.91908.8a","article-title":"Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS","volume":"66","author":"Kimura","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.eclinm.2019.100254_bib0026","unstructured":"International Conference on Harmonisation E9 Expert Working Group. ICH harmonised tripartite guideline. Statistical principles for clinical trials. Stat Med. 1999\/10\/26 ed1999. p. 1905\u201342."},{"issue":"3-4","key":"10.1016\/j.eclinm.2019.100254_bib0027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/21678421.2018.1426770","article-title":"VITALITY-ALS, a phase iii trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics","volume":"19","author":"Andrews","year":"2018","journal-title":"Amyotroph Later Scler frontotemporal Degener"},{"issue":"7-8","key":"10.1016\/j.eclinm.2019.100254_bib0028","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/21678421.2017.1353098","article-title":"Exploring the diagnosis delay and als functional impairment at diagnosis as relevant criteria for clinical trial enrolment","volume":"18","author":"Hamidou","year":"2017","journal-title":"Amyotroph Later Scler frontotemporal Degener"},{"issue":"7","key":"10.1016\/j.eclinm.2019.100254_bib0029","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.eclinm.2019.100254_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-019-03951-y","article-title":"UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis","author":"Yang","year":"2019","journal-title":"Neurol Sci"},{"issue":"7-8","key":"10.1016\/j.eclinm.2019.100254_bib0031","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/21678421.2016.1213852","article-title":"Rare genetic variation in unc13a may modify survival in amyotrophic lateral sclerosis","volume":"17","author":"Gaastra","year":"2016","journal-title":"Amyotroph Later Scler frontotemporal Degener"},{"key":"10.1016\/j.eclinm.2019.100254_bib0032","article-title":"Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis","author":"Thouvenot","year":"2019","journal-title":"Eur J Neurol"}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537019302639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537019302639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:00:48Z","timestamp":1762887648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537019302639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":32,"alternative-id":["S2589537019302639"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2019.100254","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2019.100254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100254"}}